Eupraxia Pharmaceuticals Inc. (EPRX) Stock Analysis & Investment Frameworks

Eupraxia Pharmaceuticals Inc. (EPRX) stock analysis on Invetso. Review Eupraxia Pharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Eupraxia Pharmaceuticals Inc. Company Overview

Eupraxia Pharmaceuticals Inc. Key Financial Metrics

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc. Investment Frameworks

Invetso analyzes Eupraxia Pharmaceuticals Inc. (EPRX) across the following frameworks:

Explore More EPRX Research